EGFR and non-small cell lung carcinoma: The recent AURA3 study (NCT02151981) [23] showed that AZD9291 significantly improved ORR and PFS compared with platinum/pemetrexed in T790M-positive NSCLC patients who had disease progression on first-line EGFR-TKIs.